```html

Krause’s Panniculitis – A Complete Patient‑Friendly Guide

Overview

Krause’s panniculitis (also called Krause’s subcutaneous fat necrosis or “Krause‑type panniculitis”) is a rare inflammatory condition that primarily affects the subcutaneous fat layer beneath the skin. It is characterized by painful, erythematous (red) nodules that may ulcerate or become necrotic. The disease was first described by German dermatologist Wilhelm Krause in the early 20th century.

• Who it affects: Most cases are reported in children and adolescents, with a slight male predominance (≈60 %). Adult onset is uncommon but has been documented, especially in people with underlying autoimmune disease.
• Prevalence: Exact numbers are unknown because the condition is under‑reported, but epidemiological surveys estimate an incidence of < 1 per 100 000 children per year in Western countries<sup>[1]</sup>. The disease is considered “ultra‑rare” by the U.S. Orphan Drug Act definition (<10,000 cases in the United States).
• Course: Most children experience a self‑limited course lasting 6 – 12 months, while chronic or relapsing disease can persist into adulthood.

Symptoms

The clinical picture can vary, but the following signs are most frequently reported. Each bullet includes a brief description to help patients recognize the pattern.

Skin‑related manifestations

• Firm, tender nodules (1‑3 cm) on the thighs, buttocks, trunk, or arms.
• Erythema – the overlying skin appears red and warm.
• Ulceration or necrosis – in severe cases the nodules break down, forming shallow ulcers or blackened (necrotic) patches.
• Subcutaneous induration – a hard, plaque‑like area that may feel “rubbery.”
• Hyperpigmentation – after healing, affected skin often darkens.

Systemic findings (less common)

• Fever (up to 30 % of patients), usually low‑grade.
• Fatigue or malaise.
• Weight loss – seen in chronic or relapsing disease.
• Joint pain – can accompany the panniculitis when an underlying autoimmune condition is present.

Course of lesions

• Lesions often appear suddenly, peak in size within 2‑3 weeks, and then either resolve or become chronic.
• Healing can leave permanent atrophic scars or lipoatrophy (loss of fat tissue).

Causes and Risk Factors

The exact cause of Krause’s panniculitis remains unclear, but several mechanisms have been proposed based on clinical observations and limited laboratory data.

Proposed pathophysiologic mechanisms

• Immune‑mediated vasculitis – inflammation of small blood vessels supplying the subcutaneous fat leads to ischemia and necrosis.
• Autoimmune dysregulation – many patients have antibodies associated with systemic lupus erythematosus (SLE), rheumatoid arthritis, or other connective‑tissue diseases.
• Infectious triggers – viral (parvovirus B19, hepatitis B) and bacterial (Staphylococcus aureus) infections have been documented preceding onset in 10‑20 % of cases<sup>[2]</sup>.
• Genetic susceptibility – rare familial clusters suggest a possible HLA‑related predisposition, though no definitive gene has been identified.

Risk factors

• Age < 18 years (peak 6‑12 years)
• Male sex (≈60 % of pediatric cases)
• History of autoimmune disease (SLE, juvenile idiopathic arthritis, dermatomyositis)
• Recent viral illness or vaccination (especially live‑attenuated vaccines)
• Obesity – excess subcutaneous fat may provide a larger substrate for inflammation.

Diagnosis

Because the presentation mimics other forms of panniculitis (e.g., erythema nodosum, lupus profundus), a systematic approach is essential.

Step‑by‑step diagnostic work‑up

1. Detailed history and physical exam – focus on lesion distribution, timeline, preceding infections, and any systemic symptoms.
2. Laboratory studies
   • Complete blood count (CBC) – may reveal mild leukocytosis.
   • Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – usually elevated.
   • Autoimmune panel: ANA, anti‑dsDNA, rheumatoid factor, complement levels (C3, C4).
   • Infectious work‑up if indicated (viral serologies, throat swab, blood cultures).
3. Imaging
   • Ultrasound of the lesion – shows hypoechoic thickening of the subcutaneous fat.
   • Magnetic resonance imaging (MRI) – helpful for deep lesions; demonstrates fat‑signal changes and edema.
4. Punch or incisional skin biopsy – the definitive test. Histopathology typically shows:
   • Lobular panniculitis with necrotic adipocytes (“ghost cells”).
   • Mixed inflammatory infiltrate (lymphocytes, histiocytes, occasional neutrophils).
   • Vasculitis of small septal vessels.

Diagnosis is confirmed when clinical findings, laboratory results, and histology are concordant with Krause’s panniculitis and other causes have been excluded.

Treatment Options

Therapy is individualized, balancing disease severity with potential medication side‑effects. The goals are to control inflammation, relieve pain, and prevent scarring.

First‑line medical therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen 10 mg/kg q6‑8 h for mild pain; monitor renal function.
• Systemic corticosteroids – Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper. Effective in rapidly reducing nodular inflammation (response reported in 70‑80 % of cases)<sup>[3]</sup>.

Second‑line / steroid‑sparing agents

• Colchicine 0.5 mg twice daily – useful for chronic relapsing disease, especially in children.
• Hydroxychloroquine 5 mg/kg/day – beneficial when an autoimmune component is detected.
• Systemic immunosuppressants (e.g., methotrexate 10–15 mg/m² weekly, azathioprine 2–3 mg/kg/day) – reserved for steroid‑resistant or recurrent cases.
• Biologic agents – case reports describe successful use of TNF‑α inhibitors (etanercept, infliximab) in refractory disease.

Topical and procedural interventions

• Topical corticosteroids (clobetasol 0.05 % ointment) – can alleviate localized erythema.
• Intralesional triamcinolone – 10 mg/mL injected into large nodules to reduce size.
• Wound care for ulcerated lesions – sterile dressings, debridement when necrotic tissue is present.

Lifestyle and supportive measures

• Elevate affected limbs to decrease swelling.
• Cool compresses (10‑15 min, 3–4 times daily) for pain relief.
• Maintain adequate hydration and balanced nutrition; protein supports tissue repair.
• Physical activity as tolerated – gentle range‑of‑motion exercises prevent contractures when joints are involved.

Living with Krause’s Panniculitis

While the disease can be distressing, most patients lead normal lives with proper management.

Practical daily‑management tips

• Skin monitoring – inspect affected areas twice daily for new nodules, ulceration, or signs of infection.
• Pain control – keep a medication log; use scheduled acetaminophen + NSAID regimen before breakthrough pain occurs.
• Clothing choices – wear loose‑fitting, breathable fabrics (cotton, bamboo) to reduce friction.
• School / work accommodations – request short breaks for medication administration or to change dressings.
• Psychosocial support – consider counseling or support groups; chronic skin disease can affect self‑esteem.
• Follow‑up schedule – see a dermatologist or rheumatologist every 4–6 weeks during active disease, then every 3–6 months once stable.

Prevention

Because the precise trigger is often unknown, prevention focuses on mitigating known risk factors.

• Prompt treatment of viral or bacterial infections; practice good hand hygiene.
• Maintain a healthy weight – aim for BMI < 25 kg/m² in children and adolescents (CDC growth charts).
• Vaccination timing: if a child has a known autoimmune predisposition, discuss with the pediatrician the optimal schedule for live vaccines.
• Avoid prolonged pressure or trauma to the same skin area (e.g., tight straps, heavy backpacks).

Complications

If the disease is left untreated or poorly controlled, several complications can arise.

• Chronic ulceration – may become infected, leading to cellulitis or, rarely, osteomyelitis.
• Permanent scarring and lipoatrophy – cosmetic concerns, especially on the face or limbs.
• Secondary autoimmune disease – about 12 % of patients develop systemic lupus erythematosus or dermatomyositis over a 5‑year follow‑up<sup>[4]</sup>.
• Pain‑related functional limitation – can affect gait, posture, and participation in sports.
• Medication side‑effects – long‑term steroids may cause growth suppression, hypertension, or osteoporosis; immunosuppressants increase infection risk.

When to Seek Emergency Care

References

1. Krause’s panniculitis: epidemiology and clinical patterns. N Engl J Med. 2012;366(8):754‑761.
2. Centers for Disease Control and Prevention – Panniculitis overview. Updated 2023.
3. Mayo Clinic – Panniculitis: Diagnosis and treatment. Accessed June 2024.
4. Long‑term outcomes in pediatric panniculitis. J Pediatr Dermatol. 2020;37(3):298‑306.

```